A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (SAPPHIRE-I)

Trial Profile

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (SAPPHIRE-I)

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Nov 2015

At a glance

  • Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Registrational; Therapeutic Use
  • Acronyms SAPPHIRE-I
  • Sponsors Abbott Laboratories; AbbVie
  • Most Recent Events

    • 08 Apr 2015 Results of adherence analysis of this and another trial (SAPPHIRE-II) will be presented at The International Liver Congress 2015, according to AbbVie media release.
    • 21 Nov 2014 According to an AbbVie media release, the European Commission will review the positive opinions and make a final decision in the first quarter of 2015.
    • 11 Nov 2014 Results from PEARL-II, PEARL-III, SAPPHIRE-I, SAPPHIRE-II and TURQUOISE-II trials presented at the 65th Annual Meeting of the American Association for the Study of Liver Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top